Edesa Biotech, Inc.

EDSA | $4.3 -3.7% -3.84% 5.1K

(0.0% 1d) (6.7% 1m) (291.2% 1y) (0.0% 2d) (1.8% 3d) (2.3% 7d) (117.11% volume)
Earnings Calendar: 2022-12-07
Market Cap: $ 13,828,662
http://www.edesabiotech.com
Sec Filling | Patents | 10 employees

Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.

dermatitis gastrointestinal acne treatment

add to watch list Paper trade email alert is off

Press-releases

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Published: 2024-04-11 (Crawled : 19:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| -4.8% | O: -3.95% H: 0.0% C: -0.44%
conference biotech

Edesa Biotech to Participate in Upcoming Investor Conferences
Published: 2024-04-02 (Crawled : 14:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| 3.96% | O: -0.35% H: 2.92% C: 2.92%
biotech

Edesa Biotech to Participate in Barclays Global Healthcare Conference
Published: 2024-03-07 (Crawled : 15:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| 3.36% | O: -0.12% H: 6.93% C: 0.93%
conference biotech global

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
Published: 2023-11-20 (Crawled : 00:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| 48.17% | O: -1.99% H: 14.92% C: 3.39%
biotech dermatitis results study

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug
Published: 2023-10-25 (Crawled : 23:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| 34.74% | O: 2.72% H: 0.0% C: -1.32%
drug trial

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Published: 2023-09-28 (Crawled : 15:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| -18.84% | O: 0.45% H: 0.0% C: -9.07%
drug candidate biotech results phase 2

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
Published: 2023-07-26 (Crawled : 15:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| 461.15% | O: 0.65% H: 1.22% C: -3.74%
conference biotech growth

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Published: 2023-06-28 (Crawled : 15:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| 453.49% | O: -0.4% H: 5.91% C: 3.79%
drug influenza pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
Published: 2023-06-27 (Crawled : 14:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| 457.5% | O: 0.0% H: 0.72% C: 0.72%
biotech deal

Edesa Biotech to Participate in Swiss Biotech Day
Published: 2023-04-20 (Crawled : 13:00) - biospace.com/
EDSA | $4.3 -3.7% -3.84% 5.1K

Health Technology

| 312.96% | O: -4.63% H: 4.85% C: 1.94%
day biotech

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001654954-24-004189	4	2024-04-02	2024-04-01	Buy	A	3253	111063
0001654954-24-003606	4	2024-03-25	2024-03-25	Buy	P	5000	341702
0001654954-24-002509	4	2024-03-01	2024-03-01	Buy	A	2765	107810
0001654954-24-001264	4	2024-02-03	2024-02-01	Buy	A	2978	105045